Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 15499632.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We examined whether treatment with daclizumab, a humanized monoclonal antibody specific for the interleukin-2 receptor alpha chain, was safe and efficacious in relapsing-remitting and secondary progressive multiple sclerosis patients. Nineteen ambulatory patients with clinically active disease were treated for 5 to 25 months. Seventeen patients were not responding to other immunotherapies. Daclizumab was generally well tolerated. Sustained clinical improvement (10 patients) or stabilization (9 patients) was observed. Daclizumab treatment produced significant reduction in magnetic resonance imaging activity.
Medical subject headings
- Antibodies, Monoclonal
- Multiple Sclerosis
- Receptors, Interleukin-2